Sanford Burnham drug slows liver cancer; Yale group points to targeted melanoma drugs;

> Blocking the activity of an immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer, according to investigators at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute. Release

> A group at Yale say that a subgroup of genetic mutations present in a number of melanoma skin cancer cases could point to more targeted anti-cancer therapies. Release

> An international team of scientists successfully decoded the genome and transcriptome of an as yet incurable sub-type of acute lymphoblastic leukemia. Release

> Insulin resistance has been linked to lower brain glucose metabolism in a group of late middle-age adults at risk for Alzheimer's disease, according to an article published online by JAMA Neurology. Release

Suggested Articles

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.